Novonesis AS 

$70.78
212
-$0.34-0.48% Thursday 18:06

Statistics

Day High
72.06
Day Low
72.06
52W High
72.98
52W Low
52.1
Volume
100
Avg. Volume
1,309
Mkt Cap
0
P/E Ratio
43.84
Dividend Yield
1.04%
Dividend
0.73

Upcoming

Dividends

1.04%Dividend Yield
Aug 26
$0.37
Mar 26
$0.66
Aug 25
$0.35
Apr 25
$0.62
Sep 24
$0.30
10Y Growth
4.08%
5Y Growth
4.01%
3Y Growth
6.35%
1Y Growth
5.56%

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
2.73
4.39
6.05
7.71
Expected EPS
5.8709158026115
Actual EPS
N/A

Financials

13.97%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.79BRevenue
668.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVZMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Novonesis AS in the development and marketing of medications and vaccines for various diseases, including those in areas where Novonesis may operate.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leading healthcare company that develops innovative pharmaceuticals and vaccines, directly competing with Novonesis AS in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a diversified healthcare giant that competes with Novonesis AS through its pharmaceutical division, developing drugs that may overlap with Novonesis' product portfolio.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline is a global healthcare company that competes with Novonesis AS in the pharmaceutical and healthcare market, particularly in the development of vaccines and medications.
Novartis
NVS
Mkt Cap292.35B
Novartis is a multinational pharmaceutical company that competes with Novonesis AS in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a biopharmaceutical company that competes with Novonesis AS in the discovery, development, and commercialization of new medicines and therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Novonesis AS in the development of prescription pharmaceuticals in several therapeutic areas.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a healthcare company that competes with Novonesis AS in the pharmaceutical and diagnostics industries, focusing on oncology, immunology, and infectious diseases.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is a global healthcare leader that competes with Novonesis AS in the development and marketing of therapeutic solutions in areas such as rare diseases, multiple sclerosis, and oncology.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Novonesis AS in the discovery, development, and commercialization of prescription medicines, particularly in the oncology sector.

About

Novozymes A/S, a Danish enterprise established in 1925 and headquartered in Bagsvaerd, is a leading provider of biological solutions, specializing in the production and global distribution of industrial enzymes, microorganisms, and probiotics. Its extensive reach spans across Europe, the Middle East, Africa, North America, Asia Pacific, and Latin America. The company's diverse portfolio caters to a wide array of sectors, including the food and beverage industry with innovations for baking, beverages, dairy, starch processing, and protein applications. In household care, its products enhance laundry, dishwashing, and professional cleaning. For agriculture, Novozymes supports crop production with bioyield and biocontrol technologies, alongside animal health and nutrition solutions. It also contributes to industrial processing, providing solutions for grain and technical processes, as well as bioenergy applications encompassing liquefaction, saccharification, fermentation, and the conversion of fiber and biomass. Other significant areas of focus include textile treatments (such as biopreparation, biopolishing, and denim finishing), pulp and paper production (enhancing fiber modification, bleach boosting, and deinking), and leather processing (from soaking and bating to unhairing and degreasing). Furthermore, its expertise extends to water and waste management with bioaugmentation, biogas, and sludge control technologies. Additionally, Novozymes plays a role in pharmaceuticals, offering lipases and proteases for biocatalysis and rTrypsin for cell culture, in addition to broader human health and protein-related solutions.
Show more...
CEO
Ester Baiget
Employees
11641
Country
Denmark
ISIN
DK0060336014
WKN
000A1JP9Y

Listings

0 Comments

Share your thoughts

FAQ

What is Novonesis AS stock price today?
The current price of NVZMF is $70.78 USD — it has decreased by -0.48% in the past 24 hours. Watch Novonesis AS stock price performance more closely on the chart.
What is Novonesis AS stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Novonesis AS stocks are traded under the ticker NVZMF.
Is Novonesis AS stock price growing?
NVZMF stock has fallen by -1.78% compared to the previous week, the month change is a +14.72% rise, over the last year Novonesis AS has showed a +12.85% increase.
When is the next Novonesis AS earnings date?
Novonesis AS is going to release the next earnings report on November 05, 2026.
What were Novonesis AS earnings last quarter?
NVZMF earnings for the last quarter are 0.43 USD per share, whereas the estimation was 0.62 USD resulting in a -29.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Novonesis AS revenue for the last year?
Novonesis AS revenue for the last year amounts to 4.79B USD.
What is Novonesis AS net income for the last year?
NVZMF net income for the last year is 668.54M USD.
Does Novonesis AS pay dividends?
Yes, NVZMF dividends are paid semi-annual. The last dividend per share was 0.37 USD. As of today, Dividend Yield (FWD)% is 1.04%.
How many employees does Novonesis AS have?
As of September 04, 2026, the company has 11,641 employees.
In which sector is Novonesis AS located?
Novonesis AS operates in the Materials sector.
When did Novonesis AS complete a stock split?
The last stock split for Novonesis AS was on November 28, 2011 with a ratio of 5:1.
Where is Novonesis AS headquartered?
Novonesis AS is headquartered in Lyngby, Denmark.